PI Industries Limited — PPTs, 11-08-2026: Investor Presentation

Here's a concise, retail-friendly summary for PI Industries:

**1. Business Performance:** PI Industries reported Q1FY27 consolidated revenue down 10% YoY to ₹1,702.3 Cr, with EBITDA falling 29% to ₹369.3 Cr and PAT declining 39% to ₹244.2 Cr. This was primarily due to soft global demand affecting Agchem Exports (down ~12%) and a 25% contraction in PIHS revenue. Despite challenges, domestic volumes grew ~12%, driven by a robust 50%+ increase in Biologicals.

**2. Growth Drivers or Strategy:** The company is pushing an innovation-led growth strategy, expanding into Lifesciences, specialty chemicals, and Pharma CRDMO. A strong pipeline of over 20 products is in various development stages, with 5+ new launches planned for FY27.

**3. Recent Developments:** PI commercialized three new export molecules and introduced a new peptide-based biological product in the US. The PI Health Sciences (PIHS) segment onboarded four new customers and secured an exclusive drug discovery partnership.

**4. Key Financial Metrics:** Operating cash flow for the quarter was ₹639.5 Cr, contributing to a healthy net cash balance of ₹3,793.9 Cr, providing significant investment flexibility. Net Working Capital saw an improvement, reducing by 19 days.

**5. Management Commentary / Outlook:** Management recognizes current cyclical headwinds but emphasizes a strong long-term growth outlook, buoyed by the traction in its biological business and ongoing strategic investments in R&D and capacity (₹268.5 Cr capex in Q1FY27). They anticipate continued momentum from new enquiries and a robust product pipeline.